Sanofi Report Results of Isatuximab in P-III ICARIA-MM Study for Patients with Relapsed/Refractory Multiple Myeloma (MM)

 Sanofi Report Results of Isatuximab in P-III ICARIA-MM Study for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sanofi Report Results of Isatuximab in P-III ICARIA-MM Study for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Shots:

  • The P-III study involves assessing of isatuximab (10mg/kg qw for 4 wks.) + pomalidomide & low dose dexamethasone vs pomalidomide + low dose dexamethasone monothx in 307 patients with r/r MM 96 centers in 24 countries
  • The study resulted in meeting al 1EPs with safe and effective results
  • Isatuximab is used for targeting CD38, involved in apoptosis and immunomodulatory activity, has received ODD from the US FDA & EU for r/r multiple myeloma and is evaluated in other hematologic malignancies and solid tumors

Click here read full press release/ article | Ref: Sanofi | Image:  Biospace

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post